Derek Yung
Analyst · Jefferies. Your line is now open
Thank you, Scott and good afternoon everyone. Our third quarter results reflect continued execution of the company's growth strategy in Medicare market and our investment to prepare for the important fourth quarter selling season. Third quarter revenue was $40.8 million, an increase of 30% compared to the third quarter of 2017. Third quarter commission revenue was $33.6 million, reflecting a 14% growth compared to the third quarter a year ago. In the Medicare segment, our third quarter revenue of $32.7 million grew 42% compared to the third quarter of 2017, driven by the growth in approved Medicare members and an increase in non-commissioned revenue of over 500%. We also saw an increase in member lifetime values or LTVs of our Medicare supplement and Medicare Advantage members of 9% and 3% respectively, compared to a year ago. As a reminder, under the ASC 606 accounting standard, members LTVs have a direct impact on commission revenue that we recognized during the quarter. Third quarter submitted Medicare applications increased 17%, compared to the third quarter a year ago, while approved members grew 14%. At the product level, Medicare Supplement applications grew 95%, while Medicare Advantage application growth was flat. The growth in Medicare Supplement application volume reflects the significant investment that we have made in the GoMedigap business acquired in January. As well as our increased strategic focus on a Medicare Supplement business. We expect Medicare Advantage application growth to accelerate in the fourth quarter as a result of the annual enrollment period allowing the broader Medicare population to enroll in the new plan. And when our considerable investments in marketing and sales capacity, as well as the marketing investments of our strategic partners take full effect. We also expect for our marketing investments to yield significantly more enrollments per dollar spent during the AEP compared to outside AEP as customer conversions are substantially better across both the Medicare Advantage and Medicare Supplement business line resulting in more attractive costs about acquisition. Third quarter profit from our Medicare segment was $0.5 million, compared to a loss of $5.8 million for third quarter 2017. Year-to-date, our Medicare segment profits was $2.2 million, compared to a loss of $8.7 million for the same period in 2017. Our estimated number of Medicare members was 409,888 at the end of the third quarter, an increase of 30% compared to estimated Medicare membership at the end of the third quarter of 2017. Third quarter 2018 revenue from our Individual, Family and Small Business or IFP segment was $8 million, a decline of 5% compared to a year ago. This represents a significant improvement compared to a 31% decline reported in the second quarter. As we work to establish this segment and eventually returned at the top line growth. During the quarter, a decline in approved IFP members was offset by better than expected member retention on Qualified Health Plans. Growth and commission revenue from sales of our short-term and small business products, as well as an increase in non-commission revenue, the third quarter loss from our Individual, Family and Small Business segment was $0.6 million compared to a loss of $0.4 million in the third quarter of last year. Approved members on our major medical IFP products declined 65%, compared to a year ago, while applications declined 68%. In addition to a challenging market environment, the year-over-year decline in major medical enrollments also reflects our decision to shift our marketing spend towards non-ACA products. Our estimated individual and family plan membership at the end of third quarter was 161,371 down 29% compared to estimated membership. We reported at the end of the third quarter a year ago. We also had approximately 25,000 members on short-term plan as of the end of the third quarter, a 15% increase compared to a year ago. That's made a number of members on small business products was approximately 38,000 and 16% annual increase. It is worth noting that CMS announced last week that HealthCare.gov had encountered a security breach exposing personal information but as many as 75,000 individuals. In response, CMS has taken actions to prohibit web-based entities including eHealth to enroll customers through the government portal at the time. I would further note that because of the significant decline in subsidy based enrollments that we have experienced in the last several years and our shift in marketing emphasis away from the subsidy-eligible channel. Our expectations for the new business coming from this channel during the OEP were very low. And we did not expect actions of CMS relative to HealthCare.gov to have any meaningful impact on our business in the fourth quarter or going forward. Before I get to our operating expenses, I wanted to provide more color on our non-commission revenues. During the third quarter, we generated $7.1 million in non-commission revenue with approximately $5 million coming from Medicare carrier advertising. In addition, we generated $1.4 million from the sale of Medicare and individual and family plan leads that represented excess lead capacity that would have otherwise been lost. As Scott mentioned at the beginning of the call, the sale of excess lead to the new initiative which serves to bolster the returns on our marketing investment by monetizing the leads that we cannot immediately convert in-house. This year, we have created a market for these lead at attractive rates with established business partners that giving us the ability to be more aggressive on Medicare and marketing initiatives. We expected the establishment of this marketplace to be especially impactful during the high volume selling season. Turning to our operating expenses. Third quarter GAAP operating cost of $56.2 million, grew 19%, compared to a third quarter a year ago and non-GAAP operating cost of $48.3 million, which excludes stock-based compensation change and fair value of earn-out liability of $3.8 million and amortization of intangibles through 8% but declined as a percentage of revenue compared to the third quarter a year ago. Third quarter 2018 non-GAAP marketing and advertising expense which excludes stock-based compensation expense grew approximately $2.5 million and was 38% of revenue compared to a 42% of revenue in the third quarter a year ago. In our Medicare business, we posted a double-digit percentage decline in acquisition cost per approved member for the fourth quarter in a row with total variable marketing spend growing just 5% despite a much faster growth in new enrollments. In our Individual, Family and Small Business segment, we continue to invest in marketing spend related to growth opportunities in a small group and short-term markets. Third quarter 2018 non-GAAP customer care and enrollment expenses, which excludes stock-based compensation grew by approximately $1.4 million and represented 42% of revenue compared to 50% of revenue in the third quarter of 2017. During the quarter, we continue to ramp the count of in-house Medicare agents as well increase our outsourced agent footprint ahead of the AEP to position the company to convert to significant Medicare demands volume we expect. IFE related customer care and enrollment spend declined year-over-year, reflecting primarily lower volumes enrollment in major medical products and a focus of our online enrollment platform for customer conversion. Third quarter non-GAAP technology and content costs which excludes stock-based compensation expense and non-GAAP general and administrative expense which also excludes stock-based compensation declined by $0.4 million combined compared to the third quarter of 2017. Adjusted EBITDA for the third quarter of 2018 was negative $6.9 million, compared to negative $12.5 million for the third quarter of 2017. We calculate adjusted EBITDA by adding stock-based compensation, change in fair value of earn-out liability, depreciation and amortization including the amortization of acquired intangibles, acquisition costs, restructuring charges, other income expense and income tax benefit to our GAAP net operating income. Third quarter 2018 GAAP net loss per diluted share was $0.47, compared to a net loss per diluted share of $0.12 for the third quarter of 2017. Non-GAAP loss per diluted share was $0.22 compared to net loss of $0.04 per diluted share for the third quarter of 2017. The year-over-year decline in non-GAAP EPS despite an improvement in revenue and EBITDA is due to a significant tax benefit that we recorded in the third quarter of last year. Our third quarter 2018 cash flow from operations was negative $4.9 million, compared to negative $12.9 million in the third quarter of 2017. Capital expenditures for the third quarter of 2018 were approximately $2.3 million. Our quarter-end cash balance was $20.3 million, and our commission receivable balance was approximately $266 million. As previously announced, last month we signed an agreement with Royal Bank of Canada for 40 million revolving credit facility secured by our commission receivables. This credit facility allows us for greater operational flexibility given the seasonal nature of our business and a greater potential to invest in our growth plans in the Medicare market. Currently with no balance outstanding against the revolver. With respect to guidance and based on the information currently available, we are reaffirming the revenue, adjusted EBITDA, segment revenue and profitability and earnings per share guidance for the full year 2018 that we provided on our first quarter 2018 earnings call. We undertake no obligation to further update our guidance. In closing, to echo Scott’s earlier comment, we are confident in our operational readiness with the selling season, our ability to generate strong Medicare enrollment growth and our ability to deliver on our full year guidance for our financial performance. And now we will open up the call for questions. Operator?